

Editorial Revisions made by
FDA's Office of Policy and by
FDA's Regulations Editorial Section

and

Revisions made at the Suggestion of OMB
or in Response to Comments from OMB

January 31, 2004

Jarilyn's
& Syzette's changes

References

JAN 31 2004

1. Ephedra Monograph, *Review of Natural Products*, Demarderosian, A., Ed., 2003 (DrugFacts.com, et. al. a file for authors) SR
eFacts [online], (www.factsandcomparisons.com) SR

2. Chen, K. K., and Schmidt, C. F., "Ephedrine and related substances," *Medicine* 9:1-117, 1930. SR
SR

3. Mahuang (Appendix: Mahuanggen). In Chang, H-M. and But, P. P-H, Eds. *Pharmacology and Applications of Chinese Materia Medica*, Singapore: World Scientific Publishing Co. Pte. Ltd., 1987: SR
SR

pp. 1119-1124

4. Karch, S. B., "Other naturally occurring stimulants," In Karch, S. B., *The Pathology of Drug Abuse*, Boca Raton: CRC Press, 1996: 177-198. SR
SR

5. "Phenethylamines," In Bruneton, J., *Pharmacognosy, Phytochemistry, Medicinal Plants*, New York: Laviosier Publishing, 1995: (711-715) SR
SR

6. Betz, J. M., Tab F, "Review of Plant Chemistry: Alkaloids of Ma Huang (ephedra spp.)," Food and Drug Administration, Briefing Materials for Food Advisory Committee Special Working Group on Foods Containing Ephedrine Alkaloids, Center for Food Safety and Applied Nutrition, 1-14, 1995. SR
SR

7. World Health Organization (WHO) monographs on selected medicinal plants, *Herba Ephedrae*, pp. 145-153, 1999. SR
SR

8. Oshio, H., and Tsuki, M., Matsuka, T., "Isolation of l-Ephedrine from Pinalliae Tuber," *Chemical and Pharmaceutical Bulletin* (Tokyo) 26:2096-2097, (1998).

per style guide p. 4E

9. Ghosal, S., Chauhan, R., and Mehta, R., "Alkaloids of *Sida Cordifolia*," *Phytochemical Reports*, 14:830-832, (1975).

vol. pp

SR

10. Cui, J., Zhou, T., Zhang, J., and Lou, Z., "Analysis of Alkaloids in Chinese *Ephedra* species by Gas Chromatographic Methods," *Phytochemical Analysis*, 2:116-119, (1991).

SR

11. Food and Drug Administration, Tab E: Additional Market Review Information. Briefing Materials for Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Center for Food Safety and Applied Nutrition, ~~Food and Drug Administration~~, 1-32, 1996.

PP.

made a note see b.

12. Brevoort, P., "The U.S. botanical market - An overview," *HerbalGram* 36:49-57, 1996.

capitalization style se

13. Food and Drug Administration, Hardy, C., "FDA Market Review Update Ephedrine Alkaloid-Containing Dietary Supplements," 2000.

should have been first

14. Food and Drug Administration, Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Meeting Transcript, August 1996, Docket No. 1995N-0304, TR2, vol. 72-73.

SR
okay to put F... and P... Ad... first to conform w/ Administration record.

15. Food and Drug Administration, Food Advisory Committee, Special Working Group on Foods Containing Ephedrine Alkaloids, Meeting Transcript, October 1995, Docket No. 1995-0304, TR1, vol. 40-41.

✓

16. Commission on Dietary Supplement Labels: Report of the Commission on Dietary Supplement Labels, 1997.

17. U.S. General Accounting Office (GAO), "Dietary Supplements, Uncertainties in Analyses Underlying FDA's Proposed Rule on Ephedrine Alkaloids," GAO/HEHS/GGD-99-90, 1999.

18. Food and Drug Administration, "Assessment of Public Health Risks Associated with the Use of Ephedrine Alkaloid-containing Dietary Supplements," Docket No. 2000N-1200, 2000. ^{pp. 29-30, pp. 39-41}

19. Kernan, W. N., Viscoli, C. M., Brass, L. M., Broderick, J. P., Brott, T., Feldmann, E., Morgenstern, L. B., Wilterdink, J. L., Horwitz, R. J., ^{et al.} "Phenylpropanolamine and the risk of hemorrhagic stroke," *New England Journal of Medicine*, 343:1826-1832, 2000. ^{Style guide p. 4}

20. Department of Health and Human Services, Office of Inspector General, "Adverse Event Reporting for Dietary Supplements, An Inadequate Safety Valve," OEI-01-00-00180, 2001.

21. Shekelle P., Morton, S., Maglione, M., et al., "Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects. Evidence Report/Technology Assessment," No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No 290-97-0001, Task Order No. 9), AHRQ Publication No. 03-E022, Rockville, MD, Agency for Healthcare Research and Quality, 2003. ^{600 style}

^{Docket No. 1995N-0304, BKG3, vol. 300, www.fda.gov/OHRMS/DOCKETS/198fr/95n-0304-bkg003-ref-07-01-index.htm}

22. Shekelle, P. G., Hardy, M. L., Morton, S. C., Maglione, M., Mojica, W. A., Suttrop, M. J., Rhodes, S. L., Jungvig, L., Gagne, J., ^{et al.} "Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis," *Journal of the American Medical Association* 289:1537-1545, 2003.

23. U.S. General Accounting Office (GAO), "Dietary Supplements Containing Ephedra, Health Risks and FDA's Oversight," Testimony: Before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, U.S. House of Representatives, GAO-03-1042T, 2003.

24. U.S. General Accounting Office (GAO): "Dietary Supplements: Review of Health-Related Call Records for Users of Metabolife 356," GAO-03-494, 2003. ✓

25. Caveney, S., ^{and} Starratt, A., Glutamatergic signals in Ephedra (Scientific Correspondence), *Lancet*, 372:509, 1994. ✓

26. Caveney, S., Charlet, D. A., Freitag, H., Maier-Stolte, M., ^{et al.} Starratt, A. N., "New observations on the secondary chemistry of world Ephedra (Ephedraceae)," *American Journal of Botany*, 88:1199-1208, 2001. ✓

27. Food and Drug Administration, Love, L. A., Tab E: "Evaluation of the Safety of Food Products Containing Sources of Ephedrine Alkaloids," Briefing Materials for Food Advisory Committee Special Working Group on Foods Containing Ephedrine Alkaloids, Center for Food Safety and Applied Nutrition, pp 1-51, 1995. ✓

28. Food and Nutrition Board, Institute of Medicine, *Dietary Reference Intakes: A Risk Assessment Model for Establishing Upper Intake Levels for Nutrients (1999)*, pp 1-71, Washington, DC, National Academy Press. ✓

29. Vasan, R. S., Larson, M. G., Leip, E. P., Evans, J. C., ^{et al.} O'Donnell, C. J., Kannel, W. B., Levy, D., "Impact of high-normal blood pressure on the risk of cardiovascular disease," *New England Journal of Medicine*, 345:1291-1297, 2001. ✓

29a. Vasan, R. S., ~~Massaro, J. M., Wilson, P. W., Seshadri, S., Wolf, P. A., Levy, D., D'Agostino, R. B.~~ ^{et al.}

"Antecedent blood pressure and risk of cardiovascular disease: the Framingham Heart Study," *Circulation* 105:48-53, 2002

30. Neaton, J. D., ~~Kuller, L., Stamler, J., and Wentworth, D. N.~~ Impact of systolic and diastolic blood pressure on cardiovascular mortality, ^{chapter} in Laragh, J. H. and Brenner, B. M. *Hypertension: pathophysiology, diagnosis and management*, New York: Raven Press Ltd., 127-145, 1995.

31. National Institutes of Health, Report of Ephedra Working Group to the National Advisory Council for Complementary and Alternative Medicine, (<http://nccam.nih.gov/health/alerts/ephedra/working-group.htm>)

(2003)

32. Goldman, S. A., ~~Kennedy, D. L., Graham, D. J., Gross, F. P., Kapit, R. M., Love, L. A., White, G. G.~~ ^{et al.}

"The clinical impact of adverse event reporting," *MedWatch Continuing Education Article*, 1-11, 1996.

33. Middleton, W. S., ~~Chen, K. K.~~ ^{and} "Ephedrine," *Archives of Internal Medicine*, 39:385-403, 1927.

34. Haller, C. A., ~~Benowitz, N. L.~~ ^{and} "Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids," *New England Journal of Medicine* 343:1833-1838, 2000.

35. Hoffman, B. B. and Lefkowitz, R. J. "Catecholamines, Sympathomimetic Drugs, and Adrenergic Receptor Antagonists," ^{chapter} in Hardman, J. G., Gilman, A. G., and Limbird, L. E. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, New York, St. Louis, McGraw-Hill Chapter, 199-248 1996.

SR

consistency

SR

SP

per P. 43 of style guide

SR

SR

SR

SR

36. Astrup, A., ~~Toubro, S., Cannon, S., Hein, P.~~ ^{et al.} Madsen, J., "Thermogenic synergism between ephedrine and caffeine in healthy volunteers: a double-blind, placebo-controlled study," *Metabolism*, 40:323-329, 1991.

37. Taguchi, N., ~~Nishikawa, T., Inomata, S., Faguchi, M.~~ ^{et al.} Yamashita, S., Naito, H., "Hemodynamic effects of intravenous ephedrine in infants and children anesthetized with halothane and nitrous oxide," *Anesthesia and Analgesia* 82:568-573, 1996.

38. The Xamoterol in Severe Heart Failure Study Group, "Xamoterol in severe heart failure," *Lancet* 336:1-6, 1990.

39. Packer, M., ~~Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L.~~ ^{et al.} "Effect of oral milrinone on mortality in severe chronic heart failure, The PROMISE Study Research Group," *New England Journal of Medicine*, 325:1468-1475, 1991.

40. Cowley, A. J., ~~and Skene, A. M.~~ "Treatment of severe heart failure: quantity or quality of life? A trial of enoximone," Enoximone Investigators, *British Heart Journal*, 72:226-230, 1994.

41. Brown, O. E. Adrenergic Drugs, ^{chapter} ~~In~~ ^{OIC} Smith, C. M. and Reynard, A. M., *Essentials of Pharmacology*, Philadelphia, W.B. Saunders Company, 74-84, 1995.

42. Haller, C. A., ~~Jacob, P., III~~ ^{and} Benowitz, N. L., "Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use," *Clinical Pharmacology and Therapeutics*, 71:421-432, 2002.

43. White, L. M., ~~Gardner, S. F., Gurley, B. J., Marx, M. A., Wang, P. L., Estes, M.~~^{et al.} "Pharmacokinetics and cardiovascular effects of ma-huang (*Ephedra sinica*) in normotensive adults," *Journal Clinical Pharmacology*, 37:116-122, 1997.
44. Gurley, B. J., ~~Gardner, S. F., White, L. M., Wang, P. L.~~^{and} "Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing *Ephedra sinica* (ma huang)," *Therapeutic Drug Monitoring*, 20:439-445, 1998. SK
45. Eggertsen, R., ~~Andreasson, A., Hedner, T., Karlberg, B. E., Hansson, D.~~^{et al.} "Effect of coffee on ambulatory blood pressure in patients with treated hypertension," *Journal of Internal Medicine*, 233:351-355, 1993. SK
46. Myers, M. G., ~~Reeves, R. A.~~^{and} "The effect of caffeine on daytime ambulatory blood pressure," *American Journal of Hypertension*, 4:427-431, 1991. SK
47. Jacobs, I., ~~Pasternak, H., Bell, D. G.~~^{and} "Effects of ephedrine, caffeine, and their combination on muscular endurance," *Medicine and Science in Sports and Exercise*, 35:987-994, 2003. SK
48. Berlin, I., ~~Warot, D., Aymard, G., Acquaviva, E., Legrand, M., Labarthe, B., Peyron, I., Diquet, B., Lechat, R.~~^{et al.} "Pharmacodynamics and pharmacokinetics of single nasal (5 mg and 10 mg) and oral (50 mg) doses of ephedrine in healthy subjects," *European Journal of Clinical Pharmacology*, 57:447-455, 2001. SK
49. Boozer, C. N., ~~Daly, P. A., Homel, P., Solomon, J. L., Blanchard, D., Nasser, I. A., Strauss, R., Meredith, T.~~^{et al.} "Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial," *International Journal of Obesity and Related Metabolic Disorders*, 26:593-604, 2002. SK

50. Kaplan, N., Expert Opinion: A Review of Boozer, CN et al., *Herbal Ephedra/Caffeine for Weight Loss: A 6-Month Randomized Safety and Efficacy Trial*, Review prepared for the Food and Drug Administration, 2003. SK

51. Atkinson, R., Expert Opinion: A Review of Boozer, CN et al., *Herbal Ephedra/Caffeine for Weight Loss: A 6-Month Randomized Safety and Efficacy Trial*, Review prepared for the Food and Drug Administration, 2003. ✓

52. Espeland, M., Expert Opinion: A Review of Boozer, CN et al., *Herbal Ephedra/Caffeine for Weight Loss: A 6-Month Randomized Safety and Efficacy Trial*, Review prepared for the Food and Drug Administration, 2003. ✓

53. Hajjar, I., ^{and} Kotchen, T. A., "Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000," *Journal of the American Medical Association*, 290:199-206, 2003. ✗

54. Lewington, S., ~~Clarke, R., Qizilbash, N., Peto, R., Collins, R.~~ ^{et al.}, "Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies," *Lancet*, 360:1903-1913, 2002. ✗

55. Collins, R., ~~Peto, R., MacMahon, S., Hebert, P., Fiebach, N. H., Eberlein, K. A., Godwin, J., Qizilbash, N., Taylor, J. O., Hennekens, C. H.~~ ^{et al.}, "Blood pressure, stroke, and coronary heart disease, Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context," *Lancet*, 335:827-838, 1990. ✗

56. Staessen, J. A., ~~Wang, J. G.~~ ^{and} ~~Thijs, L.~~, "Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003," *Journal of Hypertension*, 21:1055-1076, 2003. ~~SE~~

57. Neal, B., ~~MacMahon, S.~~ ^{and} ~~Chapman, N.~~, "Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials," Blood Pressure Lowering Treatment Trialists' Collaboration, *Lancet*, 356:1955-1964, 2000.

58. MacMahon, S., ~~Peto, R., Cutler, J., Collins, R., Sorlie, P., Neaton, I., Abbott, R., Godwin, J., Dyer, A., Stamler, J.~~ ^{et al.}, "Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias," *Lancet*, 335:765-774, 1990. ~~SE~~

59. Cohn, J. N., ~~Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., III, DeMets, D. L., White, B. G.~~ ^{et al.}, "A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure," Vesnarinone Trial Investigators, *New England Journal of Medicine*, 339:1810-1816, 1998. ~~SE~~

60. Hampton, J. R., ~~van Veldhuisen, D. J., Kleber, F. X., Cowley, A. J., Ardia, A., Block, P., Cortina, A., Cserhalmi, I., Follath, F., Jensen, G., Kavanakis, I., Lie, K. I., Mancina, G., Skene, A. M.~~ ^{et al.}, "Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure," Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators, *Lancet*, 349:971-977, 1997. ~~SE~~

61. Cuffe, M. S., ~~Califf, R. M., Adams, K. F., Jr., Benza, R., Bourge, R., Colucci, W. S., Massie, B. M., O'Connor, C. M., Pina, L., Quigg, R., Silver, M. A., Gheorghiu, M.~~ ^{et al.}, "Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial," *Journal of the American Medical Association*, 287:1541-1547, 2002. SK

62. Sears, M. R., "Adverse effects of beta-agonists," *Journal of Allergy and Clinical Immunology*, 110:S322-S328, 2002.

63. Wit, A. L., ~~Hoffman, B. F., Rosen, M. R.~~ ^{and}, "Electrophysiology and pharmacology of cardiac arrhythmias, IX. Cardiac electrophysiologic effects of beta adrenergic receptor stimulation and blockade. Part A," *American Heart Journal*, 90:521-533, 1975. SK

64. Mahaffey, K. W., ~~Puma, J. A., Barbagelata, N. A., DiCarli, M. F., Leeser, M. A., Browne, K. F., Eisenberg, P. R., Bolli, R., Casas, A. C., Molina-Viamonte, V., Orlandi, C., Blevins, R., Gibbons, R. J., Califf, R. M., Granger, C. B.~~ ^{et al.}, "Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial," *Journal of the American College of Cardiology*, 34:1711-1720, 1999. SK

65. Kenchaiah, S., ~~Evans, J. C., Levy, D., Wilson, P. W., Benjamin, E. J., Larson, M. G., Kannel, W. B., Vasan, R. S.~~ ^{et al.}, "Obesity and the risk of heart failure," *New England Journal of Medicine*, 347:305-313, 2002. SK

66. National Institutes of Health, National Heart, Lung, and Blood Institute, "Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report," NIH Publication ^{no italics} 98-4083:1-262, 1998, (www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm)

67. Astrup, A., ~~Breum, L., Toubro, S., Hein, P., Quaade, F.~~ ^{et al.}, "The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet, A double blind trial," *International Journal of Obesity and Related Metabolic Disorders*, 16:269-277, 1992.

68. Toubro, S., ~~Astrup, A. V., Breum, L., Quaade, F.~~ ^{and}, "Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture," *International Journal of Obesity and Related Metabolic Disorders*, 17 Suppl 1:S69-S72, 1993.

69. Quaade, F., ~~Astrup, A., Breum, L., Toubro, S., Hein, R.~~ ^{et al.}, "The effect of an ephedrine/caffeine combination as a supplement to a weight-reducing diet. A randomized, placebo-controlled, double-blind trial," *Ugeskrift for Laeger*, 154:1258-1263, 1992.

70. Toubro, S., ~~Astrup, A., Breum, L., Quaade, F.~~ ^{and}, "The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans," *International Journal of Obesity and Related Metabolic Disorders*, 17 Suppl 3:S73-S77, 1993.

71. Astrup, A., ~~Lundsgaard, C., Madsen, J., Christensen, N. J.~~ ^{and}, "Enhanced thermogenic responsiveness during chronic ephedrine treatment in man," *American Journal Clinical Nutrition* 42:83-94, 1985.

72. Astrup, A., ~~Toubro, S.~~ ^{and} "Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man," *International Journal of Obesity and Related Metabolic Disorders*, 17 Suppl 1:S41-S43, 1993.

73. Astrup, A., ~~Toubro, S., Cannon, S., Hein, P., Breum, L., Madsen, J.~~ ^{et al.} "Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers," *American Journal Clinical Nutrition*, 51:759-767, 1990.

74. Breum, L., ~~Pedersen, J. K., Ahlstrom, F., Frimodt-Moller, J.~~ ^{and} "Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice," *International Journal of Obesity*, 18:99-103, 1994.

75. Pasquali, R., ~~Baraldi, G., Cesari, M. P., Melchionda, N., Zamboni, M., Stefanini, C., Raitano, A.~~ ^{et al.} "A controlled trial using ephedrine in the treatment of obesity," *International Journal of Obesity*, 9:93-98, 1985.

76. Pasquali, R., ~~Cesari, M. P., Melchionda, N., Stefanini, C., Raitano, A., Labo, G.~~ ^{et al.} "Does ephedrine promote weight loss in low-energy-adapted obese women?," *International Journal of Obesity*, 11:163-168, 1987.

77. Pasquali, R., ~~Casimirri, F., Melchionda, N., Grossi, G., Bertoluzzi, L., Morselli Labate, A. M., Stefanini, C., Raitano, A.~~ ^{et al.} "Effects of chronic administration of ephedrine during very-low-calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects," *Clinical Science (London)*, 82:85-92, 1992.

78. Krieger, D. R., ~~Daly, P. A., Dulloo, A. G., Ransil, B. J., Young, J. B., Landsberg, L.~~ ^{et al.} "Ephedrine, caffeine and aspirin promote weight loss in obese subjects," *Transactions of the Association of American Physicians*, 103:307-312, 1990. SR

79. Daly, P. A., ~~Krieger, D. R., Dulloo, A. G., Young, J. B., Landsberg, L.~~ ^{et al.} "Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity," *International Journal of Obesity* 17 Suppl 1:S73-S78, 1993. SR

80. Horton, T. J., ~~Geissler, C. A.~~ ^{and} "Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women," *International Journal of Obesity* 15:359-366, 1991. SR

→ insert our findings report (attached copy name of report)
81. Food and Drug Administration, Memorandum: Evaluation of Scientific References Considered by RAND, 2004. JD will check SR

82. Niemann R.A., ~~Gay M.L.~~ ^{and} "Determination of Ephedrine Alkaloids and Synephrine in Dietary Supplements by Column-Switching Cation Exchange High-Performance Liquid Chromatography with Scanning-Wavelength Ultraviolet and Fluorescence Detection," *Journal of Agricultural and Food Chemistry*, 51:5630-5638, 2003. SR

83. Chua, S. S., ~~Benrimoj, S. I.~~ ^{and} "Non-prescription sympathomimetic agents and hypertension," *Medical Toxicology and Adverse Drug Experience*, 3:387-417, 1988. SR

84. Inchiosa, M. A., "Dose-related Cardiovascular Effects of Ephedrine in Humans," Report prepared for the Food and Drug Administration, 1999. July 6, SR

Insert on p. 13

79. Daly, P. A., Krieger, D. R., Dullloo, A. G., Young, J. B., Landsberg, L., "Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity," *International Journal of Obesity* 17 Suppl 1:S73-S78, 1993.
80. Horton, T. J., Geissler, C. A., "Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women," *International Journal of Obesity* 15:359-366, 1991.
- 80a. Food and Drug Administration, Memorandum, Beaton, P., M.D., Ph.D., "Review of Boozer-Daly article for ephedrine and caffeine," (January 10, 2003, amended February 2, 2004).
81. Food and Drug Administration, Memorandum: Evaluation of Scientific References Considered by RAND, 2004.
- 81a. Friedman, L.M., ^{and} Furberg, C.D., ^{and} DeMets, D.L., *Fundamentals of Clinical Trials*, 3rd Edition, Springer, New York (1998).
- 81b. Ingelfinger, J.A., Mosteller, F., ^{and} Thibodeau, L.A., ^{and} Ware, J.H., *Biostatistics in Clinical Medicine*, 3rd Edition, McGraw-Hill, New York (1994).
- 81c. Dawson, B., ^{and} Trapp, R.G., *Basic & Clinical Biostatistics*, 3rd Edition, Lange Medical Books/McGraw-Hill, New York (2001).
82. Niemann R.A., Gay M.L., "Determination of Ephedrine Alkaloids and Synephrine in Dietary Supplements by Column-Switching Cation Exchange High-Performance Liquid Chromatography with Scanning-Wavelength Ultraviolet and Fluorescence Detection." *Journal of Agricultural and Food Chemistry* 51:5630-5638, 2003.
83. Chua, S. S., Benrimoj, S. II, "Non-prescription sympathomimetic agents and hypertension," *Medical Toxicology and Adverse Drug Experience* 3:387-417, 1988.
84. Inchiosa, M. A., "Dose-related Cardiovascular Effects of Ephedrine in Humans," Report prepared for the Food and Drug Administration, July 6, 1999.
85. Inchiosa, M. A., "Bioavailability of Ephedrine Alkaloids," Report prepared for the Food and Drug Administration, June 14, 1999.
86. Food and Drug Administration, Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Meeting Transcript, II, pp. 136, 137, 203, 205, 221, 225, 227, 229-30, 236-37, 239-40, August 27-28, 1996.
87. Food and Drug Administration, Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Meeting Transcript, II, pp. 137, 233, 237, 240, 272, 277, August 27-28, 1996.

85. Inchiosa, M. A., "Bioavailability of Ephedrine Alkaloids," Report prepared for the Food and Drug Administration, 1999, June 14, SR

86. Food and Drug Administration, Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Meeting Transcript, II, 1996, pp. 136, 137, 203, 221, 225, 227, 229-230, 236, 237, and 239-240, August 27-28, 1996.

87. Food and Drug Administration, Food Advisory Committee on Dietary Supplements Containing Ephedrine Alkaloids, Meeting Transcript, II, 1996, pp. 137, 233, 237, 240, 272, and 277, August 27-28, 1996.

88. ^{Kering} Klein, K. J., Dietary Supplements Containing Ephedrine Alkaloids, Comments from Circadian Technologies, Inc., FDA Docket No. 95N-0304, 3923:1-3, 2003. ¹⁹ \$

89. Lee, M. K., Cheng, B. W., Che, C. T., Hsieh, D. P., "Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation," *Toxicological Sciences* 56:424-430, 2000. SR

90. Hikino, H., Ogata, K., Konno, C., Sato, S., "Hypotensive actions of ephedradines, macrocyclic spermine alkaloids of Ephedra roots," *Planta Medica* 48:290-293, 1983. SR

91. Minamatsu, S., Kobayashi, Y., Kobayashi, N., Fujii, Y., Aburada, M., Yamashita, M., "Acute Ephedrae Herba and ephedrine poisoning in mice," *Japanese Journal of Toxicology* 4(2), 1991. 143-149 SR

92. Lee, M. K., Wong, Y. H., Che, C. T., Hsieh, D. P. H., ^{et al.} "Adrenergic agonistic effects and cyto-toxicity of Chinese Ephedra (Ma-Huang) used for weight reduction," *Toxicological Sciences, The Toxicologist* 5, 48:58:272, 1999. SR

93. CANTOX Health Sciences International, "Safety Assessment and Determination of a Tolerable Upper Limit for Ephedra," 1-273, 2000, www.crnusa.org/cantoxreportindex.html. ^{pp.} 7
SR
94. Ad Hoc Committee Reports, On the Safety of Ma Huang (1995, 1996); On the Safety of Dietary Supplements (1997), ^{FDA} Docket No. 1995N-0304, RPT 4, vol. 36-38, 1995-0304, C57, vol. 76; 1995N-0304, C3391, vol. 280. SR
95. Ephedra Education Council Expert Panel Report, 2000, www.ephedrafacts.com/health.html#expert. ^{FDA Docket No. 2000N-1200, vol. 70} SR
96. Boozer, C. N., ~~Daly, P. A., Blanchard, D., Nasser, J. A., Solomon, I. L., Homel, P., Strauss, R., Snodgrass, W., Meredith, T.~~ ^{et al.} "Herbal ephedra/caffeine for weight loss: a 6-month safety and efficacy trial," *North American Association for the Study of Obesity*, 1-22, 2000. SR
97. Dulfano, M. J., ^{and} Glass, P., "Evaluation of a new B2 adrenergic receptor stimulant, terbutaline, in bronchial asthma. II. Oral comparison with ephedrine," *Current Therapeutic Research, Clinical and Experimental*, 15:150-157, 1973. SR
98. Tashkin, D. P., ~~Meth, R., Simmons, D. H., Lee, Y. E.~~ ^{et al.} "Double-blind comparison of acute bronchial and cardiovascular effects of oral terbutaline and ephedrine," *Chest* 68:155-161, 1975. SR
99. Brown, S. D. Jr., ^{and} Landry, F. J., "Recognizing, reporting, and reducing adverse drug reactions," *Southern Medical Journal*, 94:370-373, 2001. SR
100. Lazarou, J., ~~Pomeranz, B. H., Corey, P. N.~~ ^{and} "Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies," *Journal of the American Medical Association*, 279:1200-1205, 1998. (15)
SR

101. American Herbal Products Association, *Code of Ethics and Business Conduct*, 1-9, July 2002. ^{pp.} 

102. Lake, C. R., Quirk, R. S., "CNS stimulants and the look-alike drugs," *Psychiatric Clinics of North America*, ⁽⁴⁾ 7:689-701, 1984.

103. Furuya, I., ^{and} Watanabe, S., "Discriminative stimulus properties of ephedra herb (*Ephedra sinica*) in rats", *Yakubutsu Seishin Kodo*, 13:33-38, 1993. 

104. Tinsley, J. A., ^{and} Watkins, D. D., "Over-the-counter stimulants: abuse and addiction," *Mayo Clinic Proceedings*, 73:977-982, 1998. 

105. *Ephedra sinica*, *PDR for Herbal Medicines*, Gruenwald, J., Brendler, T., and Jaenicke, C., 1:826-827, 1998.

106. The Complete German Commission E Monographs, Therapeutic Guide to Herbal Medicines (English Translation), Blumenthal, M., Busse, W. R., Goldberg, A., Gruenwald, J., Hall, T., Riggins, C. W., and Rister, R. S., ^{pp.} 125-126, 1998.

107. Huang, K. C., Antiasthmatic herbs, ^{Chapter in,} *The pharmacology of Chinese herbs*, ^{pp.} 229-232, Boca Raton, CRC Press, 1993. 

108. Hsu, H. Y., ^{et al.} Chen, Y. P., Shen, S. J., Hsu, C. S., Chen, C. C., and Chang, H. C., Ephedrae Herba (*Ephedra*, Ma-Huang), *Oriental Materia Medica: a concise guide*, ^{pp.} 52-53, Long Beach, CA: Oriental Healing Arts Institute, 1986. 

109. Food and Drug Administration, Clinical Research and Review Staff: Evaluation of Adverse Events Reported with the Use of Ephedrine Alkaloid-containing Dietary Supplements (June 1, 1997 through March 31, 1999), 2000. ✓
SR

110. Food and Drug Administration, Chen, M., ^{and} Karwoski, C. B., Office of Post Market Drug Risk Assessment Postmarketing Safety Review, "Evaluation of Adverse Event Reports Associated with Ephedrine Alkaloid-Containing Dietary Supplements," 2000. SR

111. Woosley, R. L., "Summary of Analysis of Adverse Event Reports for Dietary Supplements Containing Ephedrine Alkaloids," Report prepared for the Food and Drug Administration, 1999. SR

112. Benowitz, N. L., "Review of Adverse Reaction Reports Involving Ephedrine-Containing Herbal Products," Report prepared for the Food and Drug Administration, 2000.

113. Ricaurte, G. A., "Review of FDA Neuropsychiatric/central nervous system adverse events related to ephedrine-containing dietary supplements," Report prepared for the Food and Drug Administration, 2000. SR

114. Stoll, A. L., "FDA Ephedrine Adverse Event Case Review: Summary," 1999.

115. Woosley, R. L., "FDA Addendum: Summary of Analysis of Adverse Event Reports for Dietary Supplements Containing Ephedrine Alkaloids," Report prepared for the Food and Drug Administration, 2000.

116. Food and Drug Administration, Love, L. A., "FDA Review of the Published Literature on the Physiological, Pharmacological and Toxic Effects of Ephedrine Alkaloids," 2000.

117. U.S. House of Representatives, Committee on Government Reform, Minority Staff Report, "Adverse Event Reports from Metabolife," 2002. ✓

118. Shekelle, P. G., E-Mail Response to Questions on the RAND report on ephedra, 2003. ✓

119. Shekelle, P. G., ~~Maglione, M., Morton, S. C.~~ "Preponderance of Evidence. Judging What to Do About Ephedra," RAND Review, 27:16-21, 2003, ✓

(www.rand.org/publications/randreview/issues/spring2003/evidence.html) accessed 7/14/2004. ✓ on January, style

check site SF

120. "Danish Medicines Agency: Letigen® has been suspended," Danish Medicines Agency 2002, ✓

(www.laegemiddelstyrelsen.dk/en/news/letigen_6_en.asp) accessed 3/3/2003. ✓

check site SF

121. "Adverse reactions Letigen," Danish Medicines Agency, 2002 Company Report, 18, 2002. ✓

122. Walker, A. M., "The Relation between Voluntary Notification and Material Risk in Dietary Supplement Safety," Report prepared for the Food and Drug Administration, 2000. ✓

123. Food and Drug Administration, Letter from Melinda Plaisier to Congressman Henry Waxman (CA) dated July 11, 2001 and Tab C (preliminary evaluation of data from American Association of Poison Control Centers) enclosed with the letter, 2001.

124. U.S. General Accounting Office (GAO), GAO Report, "Dietary Supplements: Uncertainties in Analyses Underlying FDA's Proposed Rule on Ephedrine Alkaloids," submitted to Docket No. 00N-1200, ✓

GAO, 1999 ✓

GAO, 1999, 20

20

BKG 1
vol. 32

need
last 2 pp.

125. Boozer, C. N., Nasser, J. A., Heymsfield, S. B., Wang, V., ^{et al.} Chen, G., Solomon, J. L., "An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double-blind trial," *International Journal of Obesity and Related Metabolic Disorders*, 25:316-324, 2001. SK

126. National Institutes of Health, National Heart, Lung, and Blood Institute, Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, NIH Publication No. 02-5215:1-284, 2002. SK

www.nhlbi.nih.gov/guidelines/cholesterol ^{ent. site} SK

127. Bray, G. A., ^{and} Greenway, F. L., "Current and potential drugs for treatment of obesity," *Endocrine Reviews*, 20:805-875, 1999. SK

128. Yanovski, S. Z., Yanovski, J. A., "Obesity," *New England Journal of Medicine*, 346:591-602, 2002. SK

129. Food and Drug Administration, Division of Metabolic and Endocrine Drug Products, *FDA Draft Guidance for the Clinical Evaluation of Weight-Control Drugs*, 1996.

130. International Committee on Harmonization (ICH): *Guidance for Industry. S7A Safety Pharmacology Studies for Human Pharmaceuticals*, ICH, ICH, 1-11, 2001. ^{PP}

http://www.fda.gov/cder/guidance/4461fnl.pdf ^{ck site}

131. Filozof, C., ^{and} Gonzalez, C., Motman, E., "The effect ephedrine plus caffeine after a 4-week portion-controlled diet," Ninth International Congress on Obesity, Abstract 591, August, 2002, *Ninth International Congress on Obesity* 26, Supplement 1:S156, 2002.

128. Yanovski, S. Z., Yanovski, J. A., "Obesity," *New England Journal of Medicine* 346(8):591-602, 2002.
129. Food and Drug Administration, Division of Metabolic and Endocrine Drug Products, *FDA Draft Guidance for the Clinical Evaluation of Weight-Control Drugs*, 1996.
130. International Committee on Harmonization (ICH): *Guidance for Industry. S7A Safety Pharmacology Studies for Human Pharmaceuticals*, ICH, ICH, 1-11, 2001.
<http://www.fda.gov/cder/guidance/4461fnl.pdf>.
131. Filozof, C., Gonzalez, C., Hofman, E., "The effect ephedrine plus caffeine after a 4-week portion-controlled diet," Ninth International Congress on Obesity, Abstract 591, August, 2002, *Ninth International Congress on Obesity* 26, Supplement 1:S156, 2002.
132. Food and Drug Administration, "Evidence On The Safety And Effectiveness Of Ephedra: Implications For Regulation," 2003, www.fda.gov/bbs/topics/NEWS/ephedra/whitepaper.html SK
133. Boerth, J. M., Caley, C. F., "Possible case of mania associated with ma-huang," *Pharmacotherapy*, 23(3):380-383, 2003.
134. Samenuk, D., ~~Link, M. S., Homoud, M. K., Contreras, R., Theohardes, T. C., Wang, P. J., Estes, N. A., III~~, ^{et al.} "Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine," *Mayo Clinic Proceedings* 77:12-16, 2002. SK
135. Bent, S., ~~Fiedt, T. N., Odden, M. C., Shlipak, M. G.~~, ^{and} "The relative safety of ephedra compared with other herbal products," *Annals of Internal Medicine*, 138:468-471, 2003. SK
136. Morgenstern, L. B., ~~Viscoli, C. M., Kernan, W. N., Brass, L. M., Broderick, J. P., Feldman, E., Wilterdink, J. L., Brott, T., Horwitz, R. J.~~, ^{et al.} "Use of Ephedra-containing products and risk for hemorrhagic stroke," *Neurology* 60:132-135, 2003. SK
137. Food and Drug Administration, Nightingale, S. L., FDA "Dear Colleague" letter regarding the Research on Eosinophilia-Myalgia Syndrome and Current Regulatory Status of L-Tryptophan, 2002, www.cfsan.fda.gov/~dms/ds-ltr3.html
138. Food and Drug Administration, Policy and Guidance Handbook For FDA Advisory Committees, p. 114 (1994)
139. Chyka, P. A., ~~McCommon, S. W.~~, ^{and} "Reporting of adverse drug reactions by poison control centres in the US," *Drug Safety* 23:87-93, 2000. SK
140. Office of Management and Budget: Regulatory Analysis, Circular A-4:2003, www.whitehouse.gov/omb/circulars/a004/a-4.html.

141. Shekelle P, Morton, S, Maglione M, et al., "Ephedra and Ephedrine for Weight Loss and Athletic Performance Enhancement: Clinical Efficacy and Side Effects. Evidence Report/Technology Assessment," No. 76 (Prepared by Southern California Evidence-based Practice Center, RAND, under Contract No 290-97-0001, Task Order No. 9), AHRQ Publication No. 03-E022, Rockville, MD: Agency for Healthcare Research and Quality, Table 23, 2003. S

142. Centers for Disease Control and Prevention, "Life Expectancy" (Data are for U.S. in 2001), *National Center for Health Statistics, Centers for Disease Control and Prevention, U. S. Department of Health and Human Services* 2003, (www.cdc.gov/nchs.fastats/lifexpec.htm)

143. Derdeyn, C. P., Powers, W. J., "Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease," *Stroke* 27:1944-1950, 1996. SR

144. Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project, 2001 National Statistics, The "National Bill" for Conditions Treated in Hospitals (Top 100 Clinical Classifications Software (CCS) Diagnoses), 2001, (www.hcup.ahrq.gov/HCUPnet.asp)

145. GNC Plans to drop ephedra private-label supplements, *FDC Reports - Tan Sheet*, 11-12, 1996. S

146. Redfeam, S., "Ephedra Products Thin Out: Braced for the Worst, Makers Sell New Herbs," *The Washington Post* HE01, 2003, (www.washingtonpost.com/wp-dyn/articles/A52270-2003Jan13.html) S

147. Letter Correction: The Relative Safety of Ephedra Compared with Other Herbal Products, *Annals of Internal Medicine* 138(12):1012, 2003, (www.annals.org/cgi/content/full/138/12/1012), accessed 6/17/2003. ^ on June 17, 2003.

148. Dickinson, A., Letter, "The Relative Safety of Ephedra Compared with Other Herbal Products," *Annals of Internal Medicine* 139:385-386, 2003, (www.annals.org/cgi/content/full/139/5_Part_1/385-b) accessed: 9/2/2003. ^ on September 2, 2003. SK

149. *Nutrition Business Journal*, 2002 Facts and Stats about Dietary Supplements, (obtained from www.nnfa.org/facts, 2002)

150. Kaufman, D. W., Kelly, J. P., Mitchell, A. A., "Use of ephedra-containing products in the U.S. population," Data from the Slone Survey, 2003, FDA Docket No. 1995N-0304, emc126, Vol. 297. S

151. Research Triangle Institute, "Cost of Reformulating Foods and Cosmetics," Final Report, Report prepared for the Food and Drug Administration, 2002.

152. Gugliotta, G., "Lawsuits over Ephedra on the Rise," *The Washington Post* 2000, (www.judgmentofparis.com/Liis_News.htm#Ephedra) accessed: 6/23/2000. ^ on June 23, 2000.

153. Gugliotta, G., "Woman Wins \$13.3 Million Against Dietary Company," *The Washington Post* 2001, (www.crnusa.org/mshellmedia020901wpcopy.html) accessed: 2/8/2001. ^ on February 8, 2001.

154. Prevention Magazine, "Consumer Use of Dietary Supplements," 1999. K

155. National Consumers League, National Consumers League's Survey of Consumers Using OTC, 2003.

156. Geiger, C. J., "Health claims: history, current regulatory status, and consumer research," *Journal of the American Dietetic Association*, 98(11):1312-1322, 1998. S

157. MacKinnon, D. P., Nohre, L., Cheong, J., Stacy, A. W., ^{et al.} Pentz, M. A., "Longitudinal relationship between the alcohol warning label and alcohol consumption," *Journal of Studies on Alcohol*, 62:221-227, 2001. SR

158. Food and Drug Administration, Memorandum: Label Analysis for Dietary Supplements Containing Ephedrine Alkaloids (2004). SR

159. Research Triangle Institute, Dietary Supplement Sales Information, Final Report, Report prepared for the Food and Drug Administration, Contract No. 223-96-2290, Task Order 4:1999, www.foodriskclearinghouse.umd.edu/dspd.htm, accessed 10/4/1999. SR

160. Research Triangle Institute, Survey of Manufacturing Practices in the Dietary Supplement Industry. Final Report, Report prepared for the Food and Drug Administration, RTI Project Number 6673-6:2000. www.foodriskclearinghouse.umd.edu/smpds.htm, accessed 5/17/2000. SR

161. Office of Management and Budget, *Guidance for Implementing E.O. 13132, "Federalism,"* October 28, 1999. SR